vaccination attenuated receipt live days durvalumab entry receiving tremelimumab prior 
vaccine live attenuated administration weeks study anticipation day cycle prior 
inactivated vaccines vaccination avelumab prohibited administration weeks dose trial influenza 
immunotherapy vaccines type tumor completion days weeks completed initiation oncolytic 
live receipt vaccine attenuated days dose prior study ip treatment 
vaccinated attenuated vaccines live weeks drug dose study starting tremelimumab 
vaccination live vaccine days prior start treatment minimum attenuated received 
live vaccines attenuated study days weeks vaccinations treatment prior vaccination 
